Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sitravatinib + Nivolumab in ccRCC
NCT03680521Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate. Started Oct 2018; status: completed.
02
Drugs
sitravatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03680521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680521.